LivaNova RECOVER VNS depression trial: pivotal data readout due 2026 — could unlock CMS coverage reversal for depression
Summary
LivaNova is running the RECOVER clinical trial to prove their VNS device can lift depression when drugs fail, with pivotal data scheduled to be released in 2026. The data will be the primary evidence used by CMS (Medicare) to determine if coverage policy should be reversed to include depression patients — a reversal that would significantly alter LivaNova's total addressable market. VNS for depression received FDA approval in 2005, but CMS subsequently denied coverage, limiting clinical use to those who could afford out-of-pocket costs. A positive RECOVER result would be the first clinical evidence sufficient to re-open this coverage question for the approximately 3 million US patients with treatment-resistant depression.
Why it matters
LivaNova's RECOVER readout is potentially the most commercially impactful binary event in neuromodulation in 2026. CMS reversal for VNS depression coverage would open a multi-billion dollar market that has been FDA-approved but commercially locked for nearly 20 years. The timing is particularly favorable: RECOVER data will land alongside Motif's RESONATE study initiation, creating simultaneous clinical evidence development across two VNS/BCI approaches for treatment-resistant depression.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial